Terence Friedlander, MD

Terence Friedlander, MD, University of California, San Francisco

Articles by Terence Friedlander, MD

Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 13, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Terence Friedlander, MDUromigos Live 2023 | November 6, 2023
Dr. Terence Friedlander provides his take on CheckMate 901 and the enfortumab vedotin/pembrolizumab combination.
Terence Friedlander, MDASCO 2023 | June 15, 2023
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.